Evercore ISI analyst Joshua Schimmer raised the firm’s price target on Cabaletta Bio to $18 from $14 and keeps an Outperform rating on the shares after finding a publication in The Lancet of a CD19 CAR-T experience in immunology for treatment of a patient with myositis.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CABA:
- Morgan Stanley upgrades Cabaletta Bio ahead of new drug filing
- Cabaletta Bio upgraded to Overweight from Equal Weight at Morgan Stanley
- Know Who to Follow! Here are the Top Female Analysts of 2022
- Autolus enters non-exclusive license agreement with Cabaletta
- Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
